NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company in healthcare and technology, reported Q2 2025 revenue of $13.2 million versus $17.0 million a year ago, reflecting strong e-commerce growth offset by declines in healthcare operations from lower prescription volumes and reduced 340B contract revenue. Gross margin fell to 21.8% from 34.5% on […]

Solowin (NASDAQ: SWIN), a financial services firm bridging traditional and digital assets, announced an initiative to reach US$1 billion in assets under management for its USD Money Market Real Yield Token (RYT) by the end of 2025. Launched April 15, 2025, through wholly owned subsidiary Solomon JFZ (Asia) Holdings Limited in collaboration with Standard Chartered, […]

Vision Marine Technologies (NASDAQ: VMAR), a leader in premium on-water experiences and owner of Florida-based dealership network Nautical Ventures, announced Nautical Ventures has signed a Letter of Intent with Nimbus Boats USA to exclusively distribute Nimbus powerboats on Florida’s West Coast. The agreement, expected to be finalized by March 31, 2026, would authorize Nautical Ventures […]

The Trump administration is developing a comprehensive strategy to strengthen the nation’s critical minerals production and reduce Chinese market control through guaranteed minimum pricing for domestic rare earth producers, senior White House officials revealed (https://ibn.fm/SdbJj). Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) stands uniquely positioned to capitalize on this initiative through its revolutionary RapidSX(TM) technology, which addresses […]

SuperCom (NASDAQ: SPCB), a global provider of secured e-Government, IoT, and cybersecurity solutions, reported Q2 2025 revenue of $7.14 million, with gross margin rising to 59.1% from 49.6%. Q2 operating income grew 187% to $1.1 million, while EBITDA rose 56% to $2.5 million. First-half 2025 net income climbed 79.5% to $5.3 million on gross margin […]

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharma company developing novel treatments for primary and metastatic cancers in the brain and central nervous system, announced it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, taking place virtually Aug. 19–21, 2025. To view the full press release, visit https://ibn.fm/JKPUq About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals […]

FingerMotion (NASDAQ: FNGR) announced that its subsidiary, Shanghai JiuGe Information Technology Co., Ltd., is presenting its Advanced Mobile Integrated Command and Communication Platform (C2 Platform) at the 2nd Indonesia International Emergency, Disaster Reduction and Rescue Expo, held Aug. 13–15, 2025, in Jakarta. The system integrates satellite communications, high-definition video, intelligent conferencing, UAV capabilities, and multi-network […]

Newton Golf Company (NASDAQ: NWTG), a technology-forward golf company delivering physics-based performance innovations, reported Q2 2025 revenue of $2.1 million, up 154% from $813,000 in the year-ago quarter, with gross margin improving to 67.6% from 60.1%. First-half 2025 revenue rose 182% to $3.3 million, while net loss narrowed to $2.1 million from $2.4 million. The […]

Clene (NASDAQ: CLNN), a late clinical-stage biopharma company developing treatments for neurodegenerative diseases, reported Q2 2025 results and said it has sufficient cash runway into Q1 2026. The company plans to meet with the FDA this quarter to review survival data for lead candidate CNM-Au8 in amyotrophic lateral sclerosis (ALS) and is preparing analyses of NIH-sponsored […]

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharma company leveraging its RADR(R) AI/ML platform for oncology drug discovery and development, announced Q2 2025 results and portfolio updates. The company reported complete responses in patients across two trials — LP-300 in advanced NSCLC and LP-284 in refractory diffuse large B-cell lymphoma — along with completion of LP-184 […]

Soligenix (NASDAQ: SNGX), a late-stage biopharma company developing treatments for rare diseases, reported Q2 2025 results and recent milestones. The company expects top-line Phase 2a results for SGX302 in mild-to-moderate psoriasis before year-end, along with continued updates from its investigator-initiated study of HyBryte(TM) for early-stage cutaneous T-cell lymphoma (CTCL). A confirmatory Phase 3 trial of […]

HeartBeam (NASDAQ: BEAT), a medical technology company developing personalized cardiac care solutions, reported financial and operational results for the quarter ended June 30, 2025. The company said it remains on track to receive FDA 510(k) clearance for its 12-lead ECG synthesis software for arrhythmia assessment by year-end, following positive pivotal study results showing 93.4% diagnostic […]